Does the media prefer ATAI or SLN?

In the previous week, Atai Beckley had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.65 beat Atai Beckley's score of 0.62 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RAPP or SLN?

In the previous week, Rapport Therapeutics had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Rapport Therapeutics and 3 mentions for Silence Therapeutics. Rapport Therapeutics' average media sentiment score of 1.69 beat Silence Therapeutics' score of 1.65 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor SLN or TYRA?

In the previous week, Silence Therapeutics had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Silence Therapeutics and 2 mentions for Tyra Biosciences. Silence Therapeutics' average media sentiment score of 1.65 beat Tyra Biosciences' score of 1.61 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to TSHA or SLN?

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Taysha Gene Therapies and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.65 beat Taysha Gene Therapies' score of 0.83 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend MESO or SLN?

Silence Therapeutics has a consensus target price of $55.00, indicating a potential upside of 464.10%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Does the media refer more to MESO or SLN?

In the previous week, Mesoblast had 12 more articles in the media than Silence Therapeutics. MarketBeat recorded 15 mentions for Mesoblast and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.65 beat Mesoblast's score of 0.13 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Silence Therapeutics (SLN) Competitors

$9.75 +0.46 (+4.95%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$9.77 +0.02 (+0.21%)

As of 07/14/2026 06:14 PM Eastern

Compare

SLN vs. ATAI, RAPP, TYRA, TSHA, and MESO

Should you buy Silence Therapeutics stock or one of its competitors? MarketBeat compares Silence Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silence Therapeutics include Atai Beckley (ATAI), Rapport Therapeutics (RAPP), Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.

How does Silence Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Silence Therapeutics has a net margin of -8,943.86% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Silence Therapeutics has lower revenue, but higher earnings than Atai Beckley. Silence Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	510.40	-$660.05M	-$2.23	N/A
Silence Therapeutics	$560K	822.48	-$88.61M	-$1.59	N/A

In the previous week, Atai Beckley had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.65 beat Atai Beckley's score of 0.62 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Atai Beckley presently has a consensus target price of $15.50, indicating a potential upside of 173.37%. Silence Therapeutics has a consensus target price of $55.00, indicating a potential upside of 464.10%. Given Silence Therapeutics' higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Atai Beckley has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Summary

Atai Beckley beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Silence Therapeutics has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Silence Therapeutics	$560K	822.48	-$88.61M	-$1.59	N/A

In the previous week, Rapport Therapeutics had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Rapport Therapeutics and 3 mentions for Silence Therapeutics. Rapport Therapeutics' average media sentiment score of 1.69 beat Silence Therapeutics' score of 1.65 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Rapport Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Rapport Therapeutics' return on equity of -24.78% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Rapport Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Rapport Therapeutics currently has a consensus price target of $57.86, indicating a potential upside of 39.55%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 464.10%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

98.7% of Silence Therapeutics shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Rapport Therapeutics beats Silence Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Silence Therapeutics compare to Tyra Biosciences?

Silence Therapeutics (NASDAQ:SLN) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Silence Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Tyra Biosciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Tyra Biosciences' return on equity of -42.66% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Tyra Biosciences	N/A	-42.66%	-39.79%

Silence Therapeutics currently has a consensus price target of $55.00, suggesting a potential upside of 464.10%. Tyra Biosciences has a consensus price target of $47.00, suggesting a potential upside of 42.94%. Given Silence Therapeutics' higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Silence Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	822.48	-$88.61M	-$1.59	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

In the previous week, Silence Therapeutics had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Silence Therapeutics and 2 mentions for Tyra Biosciences. Silence Therapeutics' average media sentiment score of 1.65 beat Tyra Biosciences' score of 1.61 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tyra Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Silence Therapeutics beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.

How does Silence Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Taysha Gene Therapies has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Taysha Gene Therapies' return on equity of -56.07% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Taysha Gene Therapies has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Silence Therapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.65	-$109M	-$0.38	N/A
Silence Therapeutics	$560K	822.48	-$88.61M	-$1.59	N/A

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Taysha Gene Therapies presently has a consensus price target of $12.62, suggesting a potential upside of 121.32%. Silence Therapeutics has a consensus price target of $55.00, suggesting a potential upside of 464.10%. Given Silence Therapeutics' higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 6 mentions for Taysha Gene Therapies and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.65 beat Taysha Gene Therapies' score of 0.83 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Taysha Gene Therapies beats Silence Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Silence Therapeutics (NASDAQ:SLN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Mesoblast has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Silence Therapeutics has a consensus target price of $55.00, indicating a potential upside of 464.10%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Mesoblast has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Mesoblast's return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Silence Therapeutics has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	126.00	-$102.14M	-$0.28	N/A
Silence Therapeutics	$560K	822.48	-$88.61M	-$1.59	N/A

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Mesoblast had 12 more articles in the media than Silence Therapeutics. MarketBeat recorded 15 mentions for Mesoblast and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.65 beat Mesoblast's score of 0.13 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Mesoblast and Silence Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$438.81M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	-6.13	18.77	27.01	24.38
Price / Sales	822.48	344.35	519.43	91.92
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	7.39	4.20	10.80	6.33
Net Income	-$88.61M	$65.13M	$3.59B	$331.02M
7 Day Performance	-2.01%	-2.63%	-1.47%	-0.33%
1 Month Performance	39.29%	2.14%	2.78%	-1.29%
1 Year Performance	50.23%	23.26%	28.50%	21.30%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	3.8107 of 5 stars	$9.75 +5.0%	$55.00 +464.1%	+55.3%	$438.81M	$560K	N/A	100	Positive News Gap Down
ATAI Atai Beckley	3.5975 of 5 stars	$5.19 +4.6%	$15.50 +198.7%	+108.5%	$1.91B	$4.09M	N/A	80	Options Volume
RAPP Rapport Therapeutics	3.0914 of 5 stars	$39.72 +3.0%	$57.86 +45.7%	+183.4%	$1.90B	N/A	N/A	N/A	Positive News High Trading Volume
TYRA Tyra Biosciences	2.6485 of 5 stars	$31.94 +3.5%	$47.00 +47.2%	+201.4%	$1.90B	N/A	N/A	20	Positive News
TSHA Taysha Gene Therapies	3.507 of 5 stars	$6.50 +1.9%	$12.62 +94.1%	+115.9%	$1.87B	$9.77M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. ATAI, RAPP, TYRA, TSHA, and MESO

How does Silence Therapeutics compare to Atai Beckley?

Summary

How does Silence Therapeutics compare to Rapport Therapeutics?

Summary

How does Silence Therapeutics compare to Tyra Biosciences?

Summary

How does Silence Therapeutics compare to Taysha Gene Therapies?

Summary

How does Silence Therapeutics compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. ATAI, RAPP, TYRA, TSHA, and MESO

How does Silence Therapeutics compare to Atai Beckley?

Is ATAI or SLN more profitable?

Do institutionals and insiders hold more shares of ATAI or SLN?

Which has better earnings & valuation, ATAI or SLN?

Does the media prefer ATAI or SLN?

Do analysts prefer ATAI or SLN?

Which has more risk & volatility, ATAI or SLN?

Summary

How does Silence Therapeutics compare to Rapport Therapeutics?

Which has higher valuation & earnings, RAPP or SLN?

Does the media prefer RAPP or SLN?

Is RAPP or SLN more profitable?

Which has more risk and volatility, RAPP or SLN?

Do analysts prefer RAPP or SLN?

Do institutionals & insiders hold more shares of RAPP or SLN?

Summary

How does Silence Therapeutics compare to Tyra Biosciences?

Which has more volatility & risk, SLN or TYRA?

Is SLN or TYRA more profitable?

Do analysts rate SLN or TYRA?

Which has better earnings and valuation, SLN or TYRA?

Does the media favor SLN or TYRA?

Do institutionals & insiders have more ownership in SLN or TYRA?

Summary

How does Silence Therapeutics compare to Taysha Gene Therapies?

Is TSHA or SLN more profitable?

Which has more risk & volatility, TSHA or SLN?

Which has higher valuation & earnings, TSHA or SLN?

Do institutionals and insiders have more ownership in TSHA or SLN?

Do analysts prefer TSHA or SLN?

Does the media refer more to TSHA or SLN?

Summary

How does Silence Therapeutics compare to Mesoblast?

Which has more risk and volatility, MESO or SLN?

Do analysts recommend MESO or SLN?

Is MESO or SLN more profitable?

Which has stronger earnings & valuation, MESO or SLN?

Do institutionals and insiders believe in MESO or SLN?

Does the media refer more to MESO or SLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools